All posts by: Michael Zand

International Gene Synthesis Consortium Updates Screening Protocols for Synthetic DNA Products and Services – PR Newswire (press release)

Pfizer partners to develop gene therapy to treat ALS – CNBC

CNBCPfizer partners to develop gene therapy to treat ALSCNBCSangamo Therapeutics and Pfizer said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord. The gene… Continue reading

Progenitor Life Sciences to Unveil Proprietary Next Generation “Off-the-Shelf” CAR-T Cell Development Workflow at … – Business Wire (press release)

Progenitor Life Sciences to Unveil Proprietary Next Generation “Off-the-Shelf” CAR-T Cell Development Workflow at …Business Wire (press release)Sams stated, “We are excited to present at Biotech Showcase™. This event will be an extraordinary opportun… Continue reading

CRISPR Therapeutics – Corporate Update To Jump Start 2018 – Seeking Alpha

CRISPR Therapeutics – Corporate Update To Jump Start 2018Seeking AlphaAs one of the stocks that transitioned into 2018 strong, the share price of CRISPR Therapeutics (NASDAQ:CRSP), a firm that focuses on gene-editing and CAR-T to treat cancers and gene… Continue reading

Quickly spotting rare side effects from immunotherapy – Medical Xpress

Quickly spotting rare side effects from immunotherapyMedical XpressIgor Puzanov, MD, MSCI, FACP, Professor of Oncology, Director of the Early Phase Clinical Trials Program and Section Chief of Melanoma at Roswell Park Cancer Institute, is a co-author o… Continue reading

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCC – Cancer Therapy Advisor

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCCCancer Therapy AdvisorThe treatment of metastatic renal cell carcinoma (mRCC) has undergone several major changes, with the first approval of targeted therapy in 2005 and the first approv… Continue reading

The first gene therapy approved to treat blindness has a price tag of $850000 – Business Insider

Business InsiderThe first gene therapy approved to treat blindness has a price tag of $850000Business InsiderThe first gene therapy in the U.S., approved last month to treat a rare, inherited form of blindness, now has a price tag: $850,000. That makes… Continue reading